Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Acquired by Soltis Investment Advisors LLC

Soltis Investment Advisors LLC increased its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 505.2% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 7,626 shares of the medical research company’s stock after acquiring an additional 6,366 shares during the quarter. Soltis Investment Advisors LLC’s holdings in Thermo Fisher Scientific were worth $3,967,000 at the end of the most recent quarter.

Other hedge funds have also made changes to their positions in the company. AMF Tjanstepension AB acquired a new position in shares of Thermo Fisher Scientific during the third quarter valued at $42,409,000. Valeo Financial Advisors LLC grew its position in Thermo Fisher Scientific by 4.8% during the 3rd quarter. Valeo Financial Advisors LLC now owns 4,348 shares of the medical research company’s stock worth $2,690,000 after purchasing an additional 198 shares in the last quarter. Lion Street Advisors LLC purchased a new stake in Thermo Fisher Scientific in the 3rd quarter worth about $231,000. Octavia Wealth Advisors LLC boosted its holdings in shares of Thermo Fisher Scientific by 17.1% during the third quarter. Octavia Wealth Advisors LLC now owns 425 shares of the medical research company’s stock worth $263,000 after purchasing an additional 62 shares during the period. Finally, Perfromance Wealth Partners LLC purchased a new position in shares of Thermo Fisher Scientific during the 3rd quarter valued at $202,000. Institutional investors own 89.23% of the company’s stock.

Analyst Ratings Changes

TMO has been the topic of several recent research reports. Stifel Nicolaus cut their target price on Thermo Fisher Scientific from $680.00 to $665.00 and set a “buy” rating on the stock in a report on Thursday, October 24th. Raymond James reissued an “outperform” rating and issued a $667.00 target price (up previously from $650.00) on shares of Thermo Fisher Scientific in a research note on Monday, February 3rd. Robert W. Baird decreased their price objective on Thermo Fisher Scientific from $632.00 to $622.00 and set an “outperform” rating on the stock in a report on Thursday, October 24th. Barclays cut their target price on Thermo Fisher Scientific from $620.00 to $610.00 and set an “equal weight” rating for the company in a research report on Wednesday, October 23rd. Finally, Bernstein Bank increased their price objective on Thermo Fisher Scientific from $565.00 to $625.00 and gave the stock a “market perform” rating in a research note on Tuesday, October 22nd. Four analysts have rated the stock with a hold rating and nineteen have issued a buy rating to the company’s stock. According to MarketBeat, Thermo Fisher Scientific presently has a consensus rating of “Moderate Buy” and a consensus target price of $658.00.

Insider Buying and Selling at Thermo Fisher Scientific

In other news, CEO Marc N. Casper sold 10,000 shares of the company’s stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $530.26, for a total transaction of $5,302,600.00. Following the completion of the sale, the chief executive officer now owns 111,192 shares of the company’s stock, valued at approximately $58,960,669.92. This represents a 8.25 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CFO Stephen Williamson sold 9,825 shares of the firm’s stock in a transaction on Tuesday, February 4th. The shares were sold at an average price of $585.59, for a total value of $5,753,421.75. Following the completion of the sale, the chief financial officer now directly owns 27,296 shares in the company, valued at approximately $15,984,264.64. This represents a 26.47 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 20,125 shares of company stock valued at $11,231,699 in the last three months. Corporate insiders own 0.34% of the company’s stock.

Thermo Fisher Scientific Price Performance

Thermo Fisher Scientific stock opened at $571.44 on Monday. The company has a market capitalization of $218.58 billion, a price-to-earnings ratio of 34.57, a PEG ratio of 3.18 and a beta of 0.77. The stock’s 50 day moving average is $547.34 and its 200-day moving average is $572.26. The company has a current ratio of 1.66, a quick ratio of 1.29 and a debt-to-equity ratio of 0.59. Thermo Fisher Scientific Inc. has a 12 month low of $493.30 and a 12 month high of $627.88.

Thermo Fisher Scientific (NYSE:TMO) last announced its earnings results on Thursday, January 30th. The medical research company reported $6.10 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.94 by $0.16. Thermo Fisher Scientific had a net margin of 14.78% and a return on equity of 17.51%. Equities research analysts expect that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific declared that its board has initiated a share repurchase program on Friday, November 15th that allows the company to buyback $4.00 billion in outstanding shares. This buyback authorization allows the medical research company to repurchase up to 2% of its stock through open market purchases. Stock buyback programs are generally a sign that the company’s board believes its shares are undervalued.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.